Abstract
Response to ICI per RECIST 1.1 is durable and associated with improved overall survival (OS). Benefit extends beyond responders to pts with stable disease (SD), who constitute a heterogeneous group with increase or decrease in tumor size without meeting response or progression criteria. We hypothesize that ART may better discriminate benefit translating to improved OS.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
